Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 | Zendy

MacGilchrist | Zendy; Orme | Zendy; Stephen Mitchell | Zendy; Spurden | Zendy; Bird | Zendy

Open Access

Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

Author(s) -

MacGilchrist,

Orme,

Stephen Mitchell,

Spurden,

Bird

Publication year - 2012

Publication title -

biologics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.948

H-Index - 38

eISSN - 1177-5491

pISSN - 1177-5475

DOI - 10.2147/btt.s36707

Subject(s) - medicine , rheumatoid arthritis , etanercept , randomized controlled trial , meta analysis , physical therapy , cochrane library , rheumatology , combination therapy , odds ratio

Biologic disease-modifying antirheumatic drugs (bDMARDs) extend the treatment choices for rheumatoid arthritis patients with suboptimal response or intolerance to conventional DMARDs. The objective of this systematic review and meta-analysis was to compare the relative efficacy of EU-licensed bDMARD combination therapy or monotherapy for patients intolerant of or contraindicated to continued methotrexate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research